Anixa Biosciences (ANIX) Shares Outstanding (2011 - 2026)
Anixa Biosciences' (ANIX) quarterly Shares Outstanding (Entity) came in at $33.9 million in Q2 2026, up 5.31% YoY from $32.2 million in Q2 2025, and up 104425.72% on a QoQ basis from $32454.0 in Q4 2025.
Anixa Biosciences (ANIX) Shares Outstanding (2011 - 2026) Analysis & Trends
Anixa Biosciences (ANIX) has 17 years of Shares Outstanding (Entity) data on file, last reported at $33.9 million in Q2 2026.
- Quarterly Shares Outstanding (Entity) rose 5.31% year-over-year to $33.9 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $33.9 million (up 5.31% YoY) and the FY2025 annual result came in at $32454.0, up 1.74% from the prior year.
- Shares Outstanding (Entity) advanced to $33.9 million in Q2 2026, from $32454.0 in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $33.9 million in Q2 2026 to a low of $30374.0 in Q4 2022.
- A 5-year average of $9.1 million and a median of $31914.0 in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) slumped 99.9% — and 2025, when it surged 102296.3%.
- Tracing ANIX's Shares Outstanding (Entity) over 5 years: stood at $30374.0 in 2022, then gained by 2.0% to $30980.0 in 2023, then increased by 2.96% to $31898.0 in 2024, then gained by 1.74% to $32454.0 in 2025, then surged by 104425.72% to $33.9 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $33.9 million (Q2 2026), $32454.0 (Q4 2025), and $32.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Anixa Biosciences | 123.62 Mn | 123.62 Mn | - | 33.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 33.59 Mn |
| Oct 31, 2025 | 32,454.00 |
| Jul 31, 2025 | 32.48 Mn |
| Apr 30, 2025 | 32.20 Mn |
| Jan 31, 2025 | 32.20 Mn |
| Oct 31, 2024 | 31,898.00 |
| Jul 31, 2024 | 32,054.00 |
| Apr 30, 2024 | 31,914.00 |
| Jan 31, 2024 | 31,446.00 |
| Oct 31, 2023 | 30,980.00 |
| Jul 31, 2023 | 30,974.00 |
| Apr 30, 2023 | 30,930.00 |
| Jan 31, 2023 | 30,921.00 |
| Oct 31, 2022 | 30,374.00 |
| Jul 31, 2022 | 30,451.00 |
| Apr 30, 2022 | 12.10 Mn |
| Jan 31, 2022 | 10.70 Mn |
| Oct 31, 2021 | 28.58 Mn |
| Jul 31, 2021 | 30.46 Mn |
| Apr 30, 2021 | 28.67 Mn |